Calcichew-D3 Apelsin
Calcium carbonate and colecalciferol (vitamin D3) – orange-flavored chewable tablet
Calcichew-D3 Apelsin is a combination chewable tablet containing 500 mg of elemental calcium (as calcium carbonate) and 800 IU of vitamin D3 (colecalciferol). It is prescribed for the prevention and treatment of calcium and vitamin D deficiency, as an adjunct in osteoporosis therapy, and for individuals at risk of bone loss. The orange-flavored tablet is designed to be chewed, which improves calcium absorption compared to swallowing whole tablets. This guide covers uses, dosage, side effects, drug interactions, and storage based on international guidelines.
Quick Facts
Key Takeaways
- Calcichew-D3 Apelsin provides both calcium and vitamin D3 in a single chewable tablet, ensuring optimal calcium absorption and bone mineralization
- The 800 IU vitamin D3 dose meets current international recommendations for adults at risk of deficiency, particularly the elderly and those with limited sun exposure
- Calcium supplements should be separated from certain medications (antibiotics, bisphosphonates, thyroid hormones) by at least 2–4 hours to prevent absorption interference
- Regular monitoring of blood calcium levels is recommended during treatment, especially in patients with kidney impairment or those taking thiazide diuretics
- The tablet should be chewed, not swallowed whole, and is best taken with or after food for maximum absorption
What Is Calcichew-D3 Apelsin and What Is It Used For?
Calcichew-D3 Apelsin is a combination supplement containing calcium carbonate (providing 500 mg elemental calcium) and colecalciferol (vitamin D3, 800 IU). It is used to prevent and treat calcium and vitamin D deficiency, as an adjunct in osteoporosis therapy, and to support bone health in patients at risk of bone loss.
Calcium is the most abundant mineral in the human body, with approximately 99% stored in bones and teeth. It plays a critical role in bone mineralization, nerve transmission, muscle contraction, blood clotting, and cellular signaling. The body cannot produce calcium on its own and depends entirely on dietary intake and supplementation to maintain adequate levels. When calcium intake is insufficient, the body draws calcium from the bones to maintain blood calcium levels, a process that over time leads to decreased bone density and increased fracture risk.
Vitamin D3 (colecalciferol) is equally essential for bone health. It is synthesized in the skin upon exposure to ultraviolet B (UVB) radiation from sunlight and can also be obtained from dietary sources such as oily fish, egg yolks, and fortified foods. In the body, vitamin D3 is first hydroxylated in the liver to form 25-hydroxyvitamin D (calcifediol), then further hydroxylated in the kidneys to produce 1,25-dihydroxyvitamin D (calcitriol), the biologically active form. Calcitriol acts on the intestine to increase calcium and phosphorus absorption, on the kidneys to reduce calcium excretion, and on bone to promote mineralization. Without sufficient vitamin D, only approximately 10–15% of dietary calcium is absorbed, compared to 30–40% when vitamin D levels are adequate.
The combination of calcium and vitamin D3 in a single tablet is supported by substantial clinical evidence. The landmark Women’s Health Initiative (WHI) study, along with numerous meta-analyses, has demonstrated that combined calcium and vitamin D supplementation significantly reduces the risk of hip fractures and other osteoporotic fractures, particularly in elderly populations and those with documented deficiency. Current guidelines from the International Osteoporosis Foundation (IOF), the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO), and the National Osteoporosis Foundation (NOF) all recommend combined calcium and vitamin D supplementation as a fundamental component of osteoporosis prevention and treatment.
Approved Indications
Calcichew-D3 Apelsin is prescribed for the following conditions:
- Calcium and vitamin D deficiency: Treatment and prevention of calcium and vitamin D deficiency states, particularly in elderly individuals who may have inadequate dietary intake and limited sun exposure
- Osteoporosis adjunct therapy: As a supplement alongside specific osteoporosis treatments such as bisphosphonates (alendronate, risedronate), denosumab, or selective estrogen receptor modulators (SERMs), all of which require adequate calcium and vitamin D levels to function effectively
- Osteoporosis prevention: In individuals at increased risk of osteoporosis, including postmenopausal women, elderly patients, those on long-term corticosteroid therapy, and patients with malabsorptive conditions
- Increased calcium requirements: During periods of increased calcium demand, such as pregnancy and breastfeeding (under medical supervision), adolescent growth, and post-fracture recovery
What Should You Know Before Taking Calcichew-D3 Apelsin?
Do not take Calcichew-D3 Apelsin if you have hypercalcemia (high blood calcium), hypercalciuria (excessive calcium in urine), kidney stones containing calcium, severe kidney impairment, or hypervitaminosis D. Several medications interact with calcium supplements and require dose separation. Inform your doctor about all medications you are currently taking.
Before starting Calcichew-D3 Apelsin, your doctor will assess your calcium and vitamin D status, kidney function, and review your complete medication list. Understanding the contraindications, warnings, and precautions will help ensure safe and effective use of this supplement.
Contraindications
You must not take Calcichew-D3 Apelsin if you have any of the following conditions:
- Hypercalcemia: Elevated blood calcium levels (above the normal reference range of 2.1–2.6 mmol/L), which can occur in conditions such as primary hyperparathyroidism, certain malignancies (including myeloma and bone metastases), and sarcoidosis
- Hypercalciuria: Excessive calcium excretion in the urine (greater than 7.5 mmol/24 hours or 300 mg/24 hours), which increases the risk of kidney stone formation
- Nephrolithiasis: Current kidney stones containing calcium (calcium oxalate or calcium phosphate stones)
- Nephrocalcinosis: Calcification of kidney tissue
- Severe renal impairment: Estimated glomerular filtration rate (eGFR) below 30 mL/min, as the kidneys cannot adequately excrete excess calcium or convert vitamin D to its active form
- Hypervitaminosis D: Excessive levels of vitamin D in the blood
- Allergy: Known hypersensitivity to calcium carbonate, colecalciferol, soya, peanut, or any of the excipients
Warnings and Precautions
Special care and monitoring is required if you have any of the following conditions. Your doctor should be informed before you start treatment:
- Mild to moderate kidney impairment: Calcium and vitamin D should be used with caution, with regular monitoring of blood calcium levels and kidney function. Your doctor may need to adjust the dose or frequency
- Sarcoidosis: This inflammatory condition can increase the conversion of vitamin D to its active form, potentially leading to hypercalcemia. Close monitoring of blood and urine calcium levels is essential
- History of kidney stones: Even if you do not currently have kidney stones, a history of calcium-containing stones requires careful evaluation of the risk-benefit ratio. Adequate fluid intake (at least 2 liters per day) is recommended
- Immobilization: Prolonged bed rest or immobility increases the risk of hypercalcemia because bone turnover is altered. Calcium supplementation should be used cautiously in immobilized patients
- Concurrent use of other calcium or vitamin D products: Be aware of your total daily intake from all sources (diet, supplements, fortified foods) to avoid exceeding the recommended upper limits
Your doctor may recommend periodic blood tests to measure your calcium levels (serum calcium), kidney function (creatinine, eGFR), and 25-hydroxyvitamin D levels. This monitoring is particularly important in patients with kidney impairment, elderly patients, patients taking thiazide diuretics or cardiac glycosides (digoxin), and during long-term treatment. If symptoms of hypercalcemia develop (nausea, vomiting, excessive thirst, frequent urination, constipation, or confusion), contact your doctor immediately.
Pregnancy and Breastfeeding
Calcichew-D3 Apelsin can be used during pregnancy and breastfeeding when there is a documented calcium and vitamin D deficiency, but only at the dose recommended by your doctor. During pregnancy, the recommended daily intake of calcium is 1000–1300 mg, and the developing fetus requires substantial amounts of calcium for bone and tooth formation, particularly during the third trimester.
However, it is important not to exceed the prescribed dose. During pregnancy, the daily intake of calcium should not exceed 2500 mg and vitamin D should not exceed 4000 IU (100 micrograms) from all sources. Prolonged hypercalcemia during pregnancy has been associated with adverse effects on the developing fetus, including physical and mental retardation in rare cases.
During breastfeeding, calcium and vitamin D are transferred to breast milk. This is generally not harmful to the infant, but the total dose should be taken into account if the infant is also receiving vitamin D supplementation, to avoid excessive vitamin D intake in the baby. Always consult your doctor about the appropriate dose during pregnancy and breastfeeding.
How Does Calcichew-D3 Apelsin Interact with Other Drugs?
Calcium can significantly reduce the absorption of several important medications, including certain antibiotics, bisphosphonates, thyroid hormones, and iron supplements. The key management strategy is to separate doses by 2–4 hours. Thiazide diuretics can increase the risk of hypercalcemia when combined with calcium supplements. Always inform your doctor about all medications you take.
Calcium carbonate is a highly reactive compound that can bind to (chelate) other drugs in the gastrointestinal tract, forming insoluble complexes that are poorly absorbed. This is the most common mechanism by which calcium interferes with other medications. Additionally, vitamin D can influence calcium metabolism in ways that affect the action of certain drugs. The following tables summarize the most important drug interactions:
Major Interactions (Dose Separation Required)
| Drug / Class | Interaction | Management |
|---|---|---|
| Tetracycline antibiotics (doxycycline, minocycline) | Calcium chelates tetracyclines in the GI tract, reducing their absorption by up to 50–65% | Separate by at least 2–3 hours; take antibiotic first |
| Quinolone antibiotics (ciprofloxacin, levofloxacin) | Calcium forms insoluble chelates with quinolones, significantly reducing antibiotic absorption and efficacy | Separate by at least 2 hours before or 4–6 hours after quinolone |
| Bisphosphonates (alendronate, risedronate) | Calcium markedly reduces bisphosphonate absorption (already very low at 1–3%) | Take bisphosphonate at least 30 minutes (preferably 2 hours) before calcium |
| Levothyroxine (thyroid hormone) | Calcium carbonate reduces levothyroxine absorption, potentially causing hypothyroidism | Separate by at least 4 hours; take levothyroxine on empty stomach |
| Iron supplements (ferrous sulfate, ferrous fumarate) | Calcium inhibits both heme and non-heme iron absorption when taken simultaneously | Separate by at least 2 hours |
Other Important Interactions
| Drug / Class | Interaction | Management |
|---|---|---|
| Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide) | Thiazides reduce urinary calcium excretion, increasing the risk of hypercalcemia when combined with calcium supplements | Monitor serum calcium levels regularly; dose adjustment may be needed |
| Cardiac glycosides (digoxin) | Hypercalcemia increases the risk of cardiac arrhythmias in patients taking digoxin; calcium potentiates the toxicity of digitalis glycosides | Monitor serum calcium and digoxin levels; ECG monitoring may be needed |
| Corticosteroids (prednisolone, dexamethasone) | Long-term corticosteroids reduce calcium absorption from the intestine and increase urinary calcium excretion, counteracting the effect of calcium supplements | Higher calcium and vitamin D doses may be needed; discuss with doctor |
| Orlistat (weight-loss medication) | Orlistat reduces fat absorption, which may impair absorption of fat-soluble vitamin D3 | Take Calcichew-D3 at bedtime, at least 2 hours after orlistat |
| Cholestyramine, colestipol (bile acid sequestrants) | Bile acid sequestrants reduce absorption of vitamin D3 by binding bile acids needed for fat-soluble vitamin absorption | Separate by at least 4 hours |
| Antacids containing aluminum | Calcium can increase aluminum absorption from aluminum-containing antacids, potentially leading to aluminum toxicity, especially in patients with kidney impairment | Avoid concurrent use, especially in renal impairment |
As a general rule, if you are taking any other medications, allow at least 2 hours between taking Calcichew-D3 Apelsin and other oral medications. For specific drugs (levothyroxine, quinolones), longer separation times may be needed as indicated above. Always inform your doctor and pharmacist about all medicines, supplements, and herbal products you are taking.
What Is the Correct Dosage of Calcichew-D3 Apelsin?
The usual adult dose of Calcichew-D3 Apelsin is 1–2 chewable tablets daily, providing 500–1000 mg of calcium and 800–1600 IU of vitamin D3. The exact dose depends on your individual needs, dietary calcium intake, and the condition being treated. Always follow your doctor’s instructions.
The optimal dose of calcium and vitamin D supplementation varies depending on age, dietary intake, sun exposure, underlying medical conditions, and concurrent medications. Your doctor will determine the appropriate dose based on your individual assessment. The following guidelines reflect current international recommendations:
Adults
Osteoporosis Prevention and Treatment (Adjunct)
The recommended dose is 1–2 tablets daily (500–1000 mg calcium + 800–1600 IU vitamin D3). For most adults over 50 years of age, 1 tablet twice daily is commonly prescribed to provide a total of 1000 mg calcium and 1600 IU vitamin D3. The IOF and ESCEO recommend a total daily calcium intake of 1000–1200 mg (from diet and supplements combined) and a vitamin D intake of 800–1000 IU for fracture prevention in adults over 50.
Calcium and Vitamin D Deficiency
The dose is individualized based on the severity of deficiency and blood test results. A typical starting dose is 1 tablet daily (500 mg calcium + 800 IU vitamin D3), which may be increased to 2 tablets daily based on response and monitoring. Your doctor will check your 25-hydroxyvitamin D and serum calcium levels to guide dosing.
Adjunct to Bisphosphonate Therapy
When prescribed alongside a bisphosphonate (such as alendronate or risedronate), the standard dose is 1 tablet daily or as directed by your doctor. It is critical to take the bisphosphonate at least 30 minutes before (preferably 2 hours before) the calcium supplement, as calcium can drastically reduce bisphosphonate absorption.
Elderly Patients
The dosage for elderly patients is the same as for other adults. However, elderly patients represent the population group most likely to benefit from calcium and vitamin D supplementation, as they frequently have inadequate dietary calcium intake, reduced skin synthesis of vitamin D due to less sun exposure and aging skin, and impaired intestinal calcium absorption. Studies have shown that combined calcium (1000–1200 mg/day) and vitamin D (800–1000 IU/day) supplementation reduces the risk of hip fractures by approximately 16–30% in elderly populations living in care facilities. Kidney function should be monitored regularly, as age-related decline in renal function can affect calcium and vitamin D metabolism.
Children and Adolescents
Calcichew-D3 Apelsin 500 mg/800 IU is generally not recommended for children under 12 years of age without specific medical advice, as the vitamin D content (800 IU) may exceed the recommended daily intake for younger children. For adolescents aged 12–18 years, the dose may be 1 tablet daily under medical supervision, taking into account dietary calcium intake and sun exposure. Lower-strength formulations may be more appropriate for children. Always consult a pediatrician before giving calcium and vitamin D supplements to children.
How to Take Calcichew-D3 Apelsin
The tablet should be chewed, not swallowed whole. Chewing the tablet breaks it into smaller particles that dissolve more readily in the stomach, improving calcium absorption. Take the tablet with or after a meal, as stomach acid production during meals facilitates the dissolution of calcium carbonate, and the fat content of meals aids vitamin D3 absorption. If you are taking two tablets daily, it is advisable to split the dose (one with breakfast, one with dinner), as the body absorbs calcium more efficiently in smaller doses of 500 mg or less at a time.
Missed Dose
If you forget to take a dose, take it as soon as you remember, unless it is nearly time for your next dose. In that case, skip the missed dose and take your next dose at the usual time. Do not take a double dose to make up for a missed dose. Occasional missed doses will not significantly affect your overall calcium and vitamin D status, but regular daily use is important for optimal benefit.
Overdose
If you have taken significantly more Calcichew-D3 Apelsin than prescribed, contact your doctor or local poison information center. Overdose can lead to hypercalcemia (abnormally high blood calcium levels).
Symptoms of hypercalcemia include:
- Nausea, vomiting, and loss of appetite
- Severe constipation and abdominal pain
- Excessive thirst (polydipsia) and frequent urination (polyuria)
- Muscle weakness and fatigue
- Confusion, drowsiness, and in severe cases, coma
- Cardiac arrhythmias (irregular heartbeat)
- Kidney damage (with prolonged hypercalcemia)
Treatment involves stopping all calcium and vitamin D supplements, ensuring adequate hydration, and medical management of hypercalcemia. In severe cases, intravenous fluids and loop diuretics may be needed to promote calcium excretion.
What Are the Side Effects of Calcichew-D3 Apelsin?
Calcichew-D3 Apelsin is generally well tolerated. The most common side effects are mild gastrointestinal disturbances such as constipation, bloating, flatulence, and nausea. Hypercalcemia and hypercalciuria may occur, particularly with higher doses or in patients with kidney impairment. Serious side effects are rare when taken at recommended doses.
Like all medicines, Calcichew-D3 Apelsin can cause side effects, although not everybody gets them. The side effects are primarily related to the calcium carbonate component and its effects on the gastrointestinal tract. Vitamin D3 at the doses used in this product rarely causes side effects on its own. If you experience any side effects that concern you, speak to your doctor or pharmacist.
Uncommon Side Effects
May affect up to 1 in 100 people
- Hypercalcemia (high blood calcium levels) – typically only with higher doses or in patients with predisposing conditions
- Hypercalciuria (excess calcium in urine) – may increase risk of kidney stone formation
- Constipation
- Flatulence (gas), bloating, and abdominal distension
- Nausea
- Diarrhea
- Abdominal pain
Rare Side Effects
May affect up to 1 in 1,000 people
- Skin rash, itching (pruritus), or hives (urticaria)
- Milk-alkali syndrome (hypercalcemia, metabolic alkalosis, and renal impairment) – typically only with very high calcium intake exceeding 2500 mg/day combined with absorbable alkali
Frequency Not Known
Cannot be estimated from available data
- Allergic reactions (angioedema, facial swelling, difficulty breathing) – very rare, seek immediate medical attention
- Rebound acid hypersecretion (temporary increase in stomach acid production after stopping calcium carbonate)
Contact your doctor if you experience persistent constipation, nausea, or abdominal discomfort, as these may indicate hypercalcemia. Seek immediate medical attention if you develop signs of a severe allergic reaction (swelling of the face, lips, or throat, difficulty breathing, or severe rash). If you notice symptoms of kidney stones (sudden severe pain in the back or side, blood in urine, or painful urination), contact your doctor urgently.
If you experience any side effects, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority (e.g., FDA MedWatch in the US, Yellow Card Scheme in the UK, or EMA EudraVigilance in the EU). Reporting helps to continuously monitor the benefit-risk balance of medicines.
How Should You Store Calcichew-D3 Apelsin?
Store Calcichew-D3 Apelsin below 30°C in the original container. Keep the container tightly closed to protect from moisture. Keep out of reach and sight of children. Do not use after the expiry date.
Proper storage is essential to maintain the potency of both the calcium carbonate and the vitamin D3 in Calcichew-D3 Apelsin. Vitamin D3 is sensitive to light, heat, and moisture, and can degrade if not stored correctly. Follow these guidelines:
- Temperature: Store below 30°C (86°F). Do not refrigerate or freeze. Avoid exposing the container to direct sunlight or excessive heat.
- Moisture: Keep the container tightly closed after each use to protect the tablets from moisture. Do not store in the bathroom. The orange flavor coating and the calcium carbonate can absorb moisture, leading to tablet degradation.
- Children: Keep out of the reach and sight of children at all times. The orange flavor makes these tablets potentially attractive to children, increasing the risk of accidental overdose.
- Expiry date: Do not use Calcichew-D3 Apelsin after the expiry date (EXP) stated on the container. The expiry date refers to the last day of the stated month.
- Signs of deterioration: Do not use tablets that appear discolored, crumbled, have an off smell, or show signs of moisture damage (softening, stickiness).
- Disposal: Do not dispose of medications in household waste or sewage. Return unused or expired medication to your pharmacy for safe disposal to help protect the environment.
What Does Calcichew-D3 Apelsin Contain?
Each chewable tablet contains calcium carbonate 1250 mg (equivalent to 500 mg elemental calcium) and colecalciferol concentrate (vitamin D3) 800 IU (20 micrograms). The tablet also contains excipients including sorbitol, isomalt, povidone, magnesium stearate, and orange flavoring.
Active Ingredients
Each Calcichew-D3 Apelsin chewable tablet contains two active substances:
- Calcium carbonate 1250 mg: This provides 500 mg of elemental calcium, which is the amount of calcium actually available for absorption. Calcium carbonate is the most concentrated commonly used calcium salt, containing 40% elemental calcium by weight. It requires stomach acid for dissolution, which is why it should be taken with food.
- Colecalciferol (vitamin D3) 800 IU (20 micrograms): This is the naturally occurring form of vitamin D produced in the skin. The 800 IU dose meets the current European Food Safety Authority (EFSA) and IOF recommendations for daily vitamin D intake in adults over 50 years. The vitamin D3 in the tablet is provided as a concentrated form stabilized with DL-alpha-tocopherol (vitamin E) and other excipients.
Inactive Ingredients (Excipients)
The excipients in Calcichew-D3 Apelsin include:
- Sorbitol (E420): A sugar alcohol used as a sweetener. Patients with rare hereditary fructose intolerance should not take this product
- Isomalt (E953): A sugar substitute providing sweetness without causing dental caries
- Povidone: A binder that helps maintain the tablet’s structural integrity
- Magnesium stearate: A lubricant used in manufacturing to prevent the tablet from sticking to machinery
- Fatty acid mono- and diglycerides: Emulsifying agents
- Orange flavoring: Natural and artificial orange flavoring that gives the tablet its characteristic taste, improving patient compliance
- DL-alpha-tocopherol: Vitamin E, used as an antioxidant to stabilize the vitamin D3 component
- Starch (modified): A filler and disintegrant
- Sucrose: Used in the vitamin D3 concentrate. Note: each tablet contains a small amount of sucrose
Tablet Description
Calcichew-D3 Apelsin tablets are white to off-white, round, biconvex chewable tablets with an orange flavor and smell. Each tablet weighs approximately 2.4 g and is designed to be chewed easily. The orange flavor significantly improves palatability compared to unflavored calcium tablets, which is particularly important for long-term treatment adherence.
Calcichew-D3 Apelsin may contain traces of soya and peanut (derived from the vitamin D3 concentrate). Patients with known allergy to soya or peanut should not use this product. The product also contains sorbitol and sucrose – patients with rare sugar intolerances should consult their doctor before use.
Frequently Asked Questions About Calcichew-D3 Apelsin
Calcichew-D3 contains both calcium carbonate and vitamin D3 (colecalciferol) in a single chewable tablet, whereas regular calcium tablets contain only calcium. The addition of vitamin D3 is clinically significant because vitamin D is essential for the absorption of calcium from the intestine. Without adequate vitamin D, only 10–15% of dietary calcium is absorbed, compared to 30–40% when vitamin D levels are sufficient. This combination is therefore more effective for preventing and treating calcium and vitamin D deficiency, particularly in osteoporosis management.
Calcium can interfere with the absorption of several important medications. You should separate Calcichew-D3 from tetracycline and quinolone antibiotics by at least 2–3 hours, from bisphosphonates (such as alendronate) by at least 30 minutes (preferably 2 hours), from levothyroxine (thyroid hormone) by at least 4 hours, and from iron supplements by at least 2 hours. As a general rule, allow at least 2 hours between Calcichew-D3 and any other oral medication. Always inform your doctor and pharmacist about all medications you are taking.
The duration depends on your individual situation. For osteoporosis prevention and treatment, calcium and vitamin D supplementation is typically long-term, often lifelong, especially if your dietary intake is insufficient. For correction of vitamin D deficiency, an initial treatment phase of 8–12 weeks is common, followed by maintenance dosing. Your doctor will assess your needs through periodic blood tests (serum calcium and 25-hydroxyvitamin D levels) and advise on the appropriate duration. Do not stop taking the supplement without consulting your doctor, particularly if it was prescribed alongside osteoporosis medication.
Yes, excessive intake can lead to hypercalcemia (high blood calcium). The tolerable upper intake level (UL) for total calcium (diet plus supplements) is 2000–2500 mg per day for adults, and for vitamin D it is 4000 IU (100 micrograms) per day. Symptoms of excess include nausea, vomiting, excessive thirst, frequent urination, constipation, muscle weakness, and confusion. Prolonged excessive intake can cause kidney stones, kidney damage, and soft tissue calcification. Be mindful of all sources of calcium and vitamin D in your diet and other supplements, and do not exceed your prescribed dose.
Calcichew-D3 is best taken with or after a meal. There are two reasons for this: first, calcium carbonate requires stomach acid for optimal dissolution and absorption, and stomach acid production is highest during meals. Taking calcium carbonate on an empty stomach results in significantly lower absorption. Second, vitamin D3 is fat-soluble, meaning it is absorbed more efficiently when taken with food that contains some fat. Taking the supplement with a meal also reduces the likelihood of gastrointestinal side effects such as bloating, gas, and constipation.
Calcichew-D3 Apelsin can be used during pregnancy when there is a documented need for calcium and vitamin D supplementation, but only at the dose recommended by your doctor. Adequate calcium and vitamin D are important for fetal bone development, especially during the third trimester. However, excessive intake must be avoided – the total daily intake should not exceed 2500 mg calcium and 4000 IU vitamin D from all sources. Prolonged hypercalcemia during pregnancy may harm the developing baby. Always discuss supplement use with your obstetrician or midwife.
References
- Weaver CM, Alexander DD, Boushey CJ, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporosis International. 2016;27(1):367-376. doi:10.1007/s00198-015-3386-5
- Harvey NC, Biver E, Kaufman JM, et al. The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporosis International. 2017;28(2):447-462. doi:10.1007/s00198-016-3773-6
- Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. European Journal of Endocrinology. 2019;180(4):P23-P54. doi:10.1530/EJE-18-0736
- National Institute for Health and Care Excellence (NICE). Vitamin D: supplement use in specific population groups (PH56). Updated 2024.
- World Health Organization. WHO Model List of Essential Medicines – 23rd list (2023). Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Calcium carbonate with colecalciferol. National Institute for Health and Care Excellence (NICE). Updated 2025.
- European Medicines Agency (EMA). Calcium carbonate / Colecalciferol – Summary of Product Characteristics. Accessed January 2026.
- Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53-58. doi:10.1210/jc.2010-2704
- Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3-44. doi:10.1007/s00198-018-4704-5
- Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. The Lancet Diabetes & Endocrinology. 2018;6(11):847-858. doi:10.1016/S2213-8587(18)30265-1
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology, endocrinology, and bone metabolism.
Content developed by iMedic’s medical writing team based on current international guidelines (WHO, EMA, FDA, BNF, IOF, ESCEO, NICE) and peer-reviewed pharmacological research.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in clinical pharmacology, endocrinology, and metabolic bone disease.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.